Corrigendum to “Eslicarbazepine Acetate Response in Intellectual Disability Population Versus General Population”

IF 2.7 3区医学 Q2 CLINICAL NEUROLOGY

Acta Neurologica Scandinavica Pub Date : 2025-09-22 DOI:10.1155/ane/9860292

{"title":"Corrigendum to “Eslicarbazepine Acetate Response in Intellectual Disability Population Versus General Population”","authors":"","doi":"10.1155/ane/9860292","DOIUrl":null,"url":null,"abstract":"J. Allard, C. Lawthom, W. Henley, et al., “Eslicarbazepine Acetate Response in Intellectual Disability Population Versus General Population,” Acta Neurologica Scandinavica 143, no. 3 (2020): 219-336, https://doi.org/10.1111/ane.13368.In the article titled “Eslicarbazepine Acetate Response in Intellectual Disability Population Versus General Population,” there were errors in the Abstract, Results, and Conclusions sections. These errors are shown below.Summary Note: The author has mistakenly described the data presented in Table 3 in the manuscript text—that is, the percentages for “ID” and “no ID” have been switched by accident. The areas to be corrected are as follows:Currently reads“Seizure improvement of ‘over 50%’ was lower in the ‘ID’ group (35% compared to 56%).”Should read“Seizure improvement of ‘over 50%’ was lower in the ‘no ID’ group (35% compared to 56%).”Currently reads“Seizure improvement of ‘over 50%’ was lower in the ‘ID’ group (35% compared to 56%).”Should read“Seizure improvement of ‘over 50%’ was lower in the ‘no ID’ group (35% compared to 56%).”Currently reads“The impact of ESL treatment on seizure rate (> 50% seizure reduction) is higher for our ‘no ID’ group (56%) when compared with our ‘ID’ group (35%), but this difference is not significant.”Should read“The impact of ESL treatment on seizure rate (> 50% seizure reduction) is higher for our ‘ID’ group (56%) when compared with our ‘no ID’ group (35%), but this difference is not significant.”We apologize for these errors.","PeriodicalId":6939,"journal":{"name":"Acta Neurologica Scandinavica","volume":"2025 1","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/ane/9860292","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Neurologica Scandinavica","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1155/ane/9860292","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

J. Allard, C. Lawthom, W. Henley, et al., “Eslicarbazepine Acetate Response in Intellectual Disability Population Versus General Population,” Acta Neurologica Scandinavica 143, no. 3 (2020): 219-336, https://doi.org/10.1111/ane.13368.

In the article titled “Eslicarbazepine Acetate Response in Intellectual Disability Population Versus General Population,” there were errors in the Abstract, Results, and Conclusions sections. These errors are shown below.

Summary Note: The author has mistakenly described the data presented in Table 3 in the manuscript text—that is, the percentages for “ID” and “no ID” have been switched by accident. The areas to be corrected are as follows:

Currently reads

“Seizure improvement of ‘over 50%’ was lower in the ‘ID’ group (35% compared to 56%).”

Should read

“Seizure improvement of ‘over 50%’ was lower in the ‘no ID’ group (35% compared to 56%).”

Currently reads

“Seizure improvement of ‘over 50%’ was lower in the ‘ID’ group (35% compared to 56%).”

Should read

“Seizure improvement of ‘over 50%’ was lower in the ‘no ID’ group (35% compared to 56%).”

Currently reads

“The impact of ESL treatment on seizure rate (> 50% seizure reduction) is higher for our ‘no ID’ group (56%) when compared with our ‘ID’ group (35%), but this difference is not significant.”

Should read

“The impact of ESL treatment on seizure rate (> 50% seizure reduction) is higher for our ‘ID’ group (56%) when compared with our ‘no ID’ group (35%), but this difference is not significant.”

We apologize for these errors.

查看原文本刊更多论文

“智力残疾人群与普通人群对醋酸埃斯卡巴西平的反应”的更正

J. Allard， C. Lawthom， W. Henley等，“智力残疾人群与普通人群的醋酸埃斯利卡巴西平反应”，《斯堪的纳维亚神经科学学报》143，第2期。3 (2020): 219-336, https://doi.org/10.1111/ane.13368.In题为“智力残疾人群与普通人群的醋酸埃斯卡巴西平反应”的文章，摘要，结果和结论部分存在错误。这些错误如下所示。注：作者在原稿文本中对表3所示数据的描述有误，即“ID”和“no ID”的百分比误调。需要更正的部分如下：目前的内容是“‘超过50%’的癫痫发作改善在‘ID’组中较低（35%对56%）。”应该读为“超过50%的癫痫发作改善在无ID组更低（35%对56%）。”目前的情况是，“超过50%”的癫痫发作改善率在“ID”组中较低（35%对56%）。应该读为“超过50%的癫痫发作改善在无ID组更低（35%对56%）。”目前的研究结果是“ESL治疗对癫痫发作率的影响（癫痫发作减少50%）在无ID组（56%）高于有ID组（35%），但这种差异并不显著。”应该阅读“ESL治疗对癫痫发作率的影响（>； 50%癫痫发作减少）在“ID”组（56%）高于“无ID”组（35%），但这种差异并不显著。”我们为这些错误道歉。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Acta Neurologica Scandinavica 医学-临床神经学

CiteScore

6.70

自引率

2.90%

发文量

161

审稿时长

4-8 weeks

期刊介绍： Acta Neurologica Scandinavica aims to publish manuscripts of a high scientific quality representing original clinical, diagnostic or experimental work in neuroscience. The journal''s scope is to act as an international forum for the dissemination of information advancing the science or practice of this subject area. Papers in English will be welcomed, especially those which bring new knowledge and observations from the application of therapies or techniques in the combating of a broad spectrum of neurological disease and neurodegenerative disorders. Relevant articles on the basic neurosciences will be published where they extend present understanding of such disorders. Priority will be given to review of topical subjects. Papers requiring rapid publication because of their significance and timeliness will be included as ''Clinical commentaries'' not exceeding two printed pages, as will ''Clinical commentaries'' of sufficient general interest. Debate within the speciality is encouraged in the form of ''Letters to the editor''. All submitted manuscripts falling within the overall scope of the journal will be assessed by suitably qualified referees.